Contrasting the reinforcing effects of the novel dopamine transport inhibitors JJC8-088 and JJC8-091 in monkeys: Potential translation to medication assisted treatment.

IF 3.8 3区 医学 Q2 PHARMACOLOGY & PHARMACY Journal of Pharmacology and Experimental Therapeutics Pub Date : 2025-01-01 Epub Date: 2024-11-22 DOI:10.1124/jpet.124.002356
Mia I Allen, Omeed Rahimi, Bernard N Johnson, Jianjing Cao, Amy Hauck Newman, Michael A Nader
{"title":"Contrasting the reinforcing effects of the novel dopamine transport inhibitors JJC8-088 and JJC8-091 in monkeys: Potential translation to medication assisted treatment.","authors":"Mia I Allen, Omeed Rahimi, Bernard N Johnson, Jianjing Cao, Amy Hauck Newman, Michael A Nader","doi":"10.1124/jpet.124.002356","DOIUrl":null,"url":null,"abstract":"<p><p>Despite considerable efforts, there remains no Food and Drug Administration-approved medications for cocaine use disorder. One strategy to mitigate cocaine craving and relapse is to elevate dopamine. The dopamine transport inhibitor and releaser d-amphetamine has been shown to decrease cocaine self-administration (SA), although it has abuse liability. Recently, several modafinil analogs reduced cocaine SA in rats and monkeys, including JJC8-088, characterized as \"cocaine-like\" in rats, and JJC8-091, characterized as \"atypical\" and not SA by rats. The present study evaluated the reinforcing effects of both compounds in monkeys under several conditions. For experiment 1, 4 male cocaine-experienced rhesus monkeys self-administered cocaine (0.001-0.3 mg/kg per injection), JJC8-088 (0.001-0.3 mg/kg per injection), and JJC8-091 (0.1-3.0 mg/kg per injection) under a progressive-ratio schedule of reinforcement. Both JJC compounds functioned as reinforcers with equal reinforcing strength to cocaine. Although JJC8-091 was less potent than cocaine, JJC8-088 and cocaine had similar potencies. For experiment 2, 1 male and 2 female drug-naïve cynomolgus monkeys responded on a fixed-ratio schedule of food reinforcement. JJC8-091 was self-administered at rates higher than saline in all 3 monkeys. In experiment 3, monkeys from experiment 2 responded under a concurrent drug versus food choice paradigm and given access to cocaine or JJC8-091 under these conditions. At doses equal to or one-half log-units higher than doses used in experiment 2, cocaine, but not JJC8-091, was chosen over food. Together, these results demonstrate that although JJC8-091 may be reinforcing under some conditions, its reinforcing strength, in the presence of an alternative reinforcer, is substantially less than cocaine. SIGNIFICANCE STATEMENT: JJC8-088 and JJC8-091 have shown efficacy is reducing cocaine self-administration (SA) in rats and in nonhuman primates. This study found that both compounds maintained SA in monkeys responding under several conditions. However, when given access to an alternative reinforcer during the SA session, JJC8-091 was not reinforcing, suggesting that JJC8-091 may have lower abuse liability than cocaine and may be a viable candidate for cocaine use disorder because, in the human population, alternatives to drug use are often available.</p>","PeriodicalId":16798,"journal":{"name":"Journal of Pharmacology and Experimental Therapeutics","volume":"392 1","pages":"100033"},"PeriodicalIF":3.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822870/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology and Experimental Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1124/jpet.124.002356","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Despite considerable efforts, there remains no Food and Drug Administration-approved medications for cocaine use disorder. One strategy to mitigate cocaine craving and relapse is to elevate dopamine. The dopamine transport inhibitor and releaser d-amphetamine has been shown to decrease cocaine self-administration (SA), although it has abuse liability. Recently, several modafinil analogs reduced cocaine SA in rats and monkeys, including JJC8-088, characterized as "cocaine-like" in rats, and JJC8-091, characterized as "atypical" and not SA by rats. The present study evaluated the reinforcing effects of both compounds in monkeys under several conditions. For experiment 1, 4 male cocaine-experienced rhesus monkeys self-administered cocaine (0.001-0.3 mg/kg per injection), JJC8-088 (0.001-0.3 mg/kg per injection), and JJC8-091 (0.1-3.0 mg/kg per injection) under a progressive-ratio schedule of reinforcement. Both JJC compounds functioned as reinforcers with equal reinforcing strength to cocaine. Although JJC8-091 was less potent than cocaine, JJC8-088 and cocaine had similar potencies. For experiment 2, 1 male and 2 female drug-naïve cynomolgus monkeys responded on a fixed-ratio schedule of food reinforcement. JJC8-091 was self-administered at rates higher than saline in all 3 monkeys. In experiment 3, monkeys from experiment 2 responded under a concurrent drug versus food choice paradigm and given access to cocaine or JJC8-091 under these conditions. At doses equal to or one-half log-units higher than doses used in experiment 2, cocaine, but not JJC8-091, was chosen over food. Together, these results demonstrate that although JJC8-091 may be reinforcing under some conditions, its reinforcing strength, in the presence of an alternative reinforcer, is substantially less than cocaine. SIGNIFICANCE STATEMENT: JJC8-088 and JJC8-091 have shown efficacy is reducing cocaine self-administration (SA) in rats and in nonhuman primates. This study found that both compounds maintained SA in monkeys responding under several conditions. However, when given access to an alternative reinforcer during the SA session, JJC8-091 was not reinforcing, suggesting that JJC8-091 may have lower abuse liability than cocaine and may be a viable candidate for cocaine use disorder because, in the human population, alternatives to drug use are often available.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对比新型多巴胺转运抑制剂JJC8-088和JJC8-091在猴子中的强化作用:可能转化为药物辅助治疗。
尽管付出了巨大的努力,食品和药物管理局仍然没有批准治疗可卡因使用障碍的药物。减轻可卡因渴望和复发的一个策略是提高多巴胺。多巴胺转运抑制剂和释放剂d-安非他明已被证明可以减少可卡因的自我给药(SA),尽管它有滥用的危险。最近,几种莫达非尼类似物降低了大鼠和猴子的可卡因SA,包括JJC8-088,在大鼠中表现为“可卡因样”,JJC8-091,在大鼠中表现为“非典型”,而不是SA。本研究评估了这两种化合物在几种条件下对猴子的强化作用。在实验1中,4只有可卡因经验的雄性恒河猴按照递进比例强化计划,自行给药可卡因(0.001 ~ 0.3 mg/kg /针)、JJC8-088 (0.001 ~ 0.3 mg/kg /针)和JJC8-091 (0.1 ~ 3.0 mg/kg /针)。两种JJC化合物都具有与可卡因相同的增强作用。虽然JJC8-091的效价低于可卡因,但JJC8-088与可卡因的效价相似。在实验2中,1只雄性和2只雌性食蟹猴drug-naïve对固定比例的食物强化计划做出反应。在所有3只猴子中,JJC8-091的自我给药率高于生理盐水。在实验3中,实验2中的猴子在药物与食物的同时选择范式下做出反应,并在这些条件下获得可卡因或JJC8-091。当剂量等于或比实验2中使用的剂量高一个半对数单位时,选择可卡因而不是食物,而不是JJC8-091。总之,这些结果表明,尽管JJC8-091可能在某些条件下增强,但在存在替代增强物的情况下,其增强强度大大低于可卡因。意义声明:JJC8-088和JJC8-091在大鼠和非人灵长类动物中显示出减少可卡因自我给药(SA)的功效。该研究发现,这两种化合物在几种条件下维持猴子的SA反应。然而,当在SA会话期间获得替代强化剂时,JJC8-091没有强化,这表明JJC8-091可能比可卡因具有更低的滥用倾向,并且可能是可卡因使用障碍的可行候选者,因为在人群中,药物使用的替代品通常是可用的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.90
自引率
0.00%
发文量
115
审稿时长
1 months
期刊介绍: A leading research journal in the field of pharmacology published since 1909, JPET provides broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology.
期刊最新文献
Moving beyond shock: Rich-lean transition procedures as a modern approach to anxiolytic screening. Multiomics and experimental validation reveal theophylline's mechanism targeting IL1A/ACTB/TLR4 and identify synergistic drugs in hepatocellular carcinoma. Downregulation of osteoclast differentiation and activation by the soluble epoxide hydrolase inhibition. Alternative reinforcement reduces oxycodone self-administration in male and female monkeys: Implications for treating opioid use disorder. Discovery of a pyridine-piperazine-based small molecule that enhances the activity of peptidase neurolysin.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1